Get started

NVAX

Trading Novavax after BreakoutNVAX jumped roughly 20% overnight after announcing 96.4% efficacy against the disease caused by the original COVID-19 strain. This single move caused the shares to break out from the downside channel and crack through the 50-day and 20-day moving averages. With this important resistance zone left behind, the shares are poised to open just above the yearly Fibonacci R2 and monthly S1 levels ($216 and $213; RY2 and SM1 lines on the chart). The question is whether the bulls can push the stock even higher today. Personally, I do not rule out that such a powerful upside gap - amid broader market concerns - could trigger some profit taking. Therefore, I will be watching to see if the stock can hold the RY2 / SM1 zone. If this happens, we can see NVAX approaching the $250 zone followed by the monthly pivot level ($258, PM) near-term. On the downside , a break below RY2 / SM1 will put the 20- and 50-day moving averages to the test. An even more bearish scenario involves retesting recent diagonal resistance and potential gap filling at $188. This zone, however, should serve as very strong support, where we will definitely see buybacks.
NASDAQ:NVAX
by tbiktag
It's unbelievable where this is sitting right now..This is a nice example of how following who's involved can lead to excellent opportunities. Just look at $SAVA. In the Christmas months of 2019, multiple insiders were seen purchasing $100's of thousands worth of shares immediately before the share price skyrocketed several hundred percent. Fast forward 13 months later, and the price broke $100.. Still, many times, you question whether these sharp intraday rallies are the product of market manipulation, as they always seem to happen immediately before heavy sell offs, but who knows..
NASDAQ:NVAX
by stocktradez6
NVAX coming back 400+ soonHey guys so NVAX had a nice bounce today from its open at 240 and closed at 273.98. It was a solid day I'm not too happy about the volume though due to it being pretty low. The stock is not going to have a tremendous move if there is no volume. We need to have above average volume to see a nice spike above 300 again. Now with the EU news coming possibly end of this week or next week I believe NVAX is going to skyrocket. I am still staying strong with my bullish target of 400 by end of February due to the amount of volume and buy orders we are going to have with the incredible EU deal. Even if EU does not come out this week we still are very oversold on the indicators and have destroyed Pfizer’s new SA variant numbers which show only 20% effectiveness on the new variant. Ours is 60% if you forgot, so we are in good shape right now do not be intimidated by shorts and hold strong!!
NASDAQ:NVAXLong
by Stockguy222
5
This is what I see for NVAX for 2021 huge gains are coming inNVAX stock has had a massive explosion from January where the stock hit 294 a share yesterday. Now I had a prediction that NVAX would break 300 a share by March I think it will be much sooner now. With all the orders and revenue stream that will be produced in 2021, we could see total revenue of 16 billion dollars. I am firmly confident we can reach the same market cap as Moderna as our vaccine is currently more effective and we have more vaccine orders. You may think I am crazy when I predict 1200 a share in a year but if you do the math and see the data it becomes quite convincing. I am not gonna even think about selling until this stock reaches over 500 which I believe could come in May.
NASDAQ:NVAXLong
by Stockguy222
3
CDXC 4.8: Small Float Biotech backed by Li Ka Shing In this market where SPEC trades at billions with NO revenue, I like CDXC though I may be early. Yes it's not TSLA, yes Value does not work in this market but With a tiny market cap of 290 mil and revenue growth at 40% (still early-stage market), I am betting with Li Ka Shing, one of the richest and other top 20 institutions including Blackrock who collectively owns 55% of the stock. Short interest is small at 7%. The better story is that the stock has been basing for a long time, and technicals are improving. I don't want to wait for breakout then buy as by then I would be paying too much a premium. So good enough for me with the IMPROVING technicals and a largely positive trend, and a real growth story. investors.chromadex.com asia.nikkei.com Top Shareholders Top 25 shareholders own 54.62% of the company Ownership Name Shares Current Value Change % Portfolio % 10.49% Ka-shing Li 6,500,937 $31.4m 0% no data 10.29% Hoi Shuen Chau 6,377,783 $30.8m 0% no data 4.53% BlackRock, Inc. 2,804,544 $13.5m -0.81% no data 3.97% The Vanguard Group, Inc. 2,461,485 $11.9m 9.03% no data 3.8% Li Ka Shing (Global) Foundation, Endowment Arm 2,353,139 $11.4m 0% 3.25% 3.11% Phillip and Patricia Frost Philanthropic Foundation, Inc, Endowment Arm 1,929,542 $9.3m 0% 42.91% 2.76%
NASDAQ:CDXCLong
by Jonas99
2